Core Insights - Supernus Pharmaceuticals reported $149.82 million in revenue for Q1 2025, a year-over-year increase of 4.3% and a surprise of +2.91% over the Zacks Consensus Estimate of $145.59 million [1] - The company achieved an EPS of $0.42, compared to $0.00 a year ago, with an EPS surprise of +10.53% against the consensus estimate of $0.38 [1] Revenue Breakdown - Trokendi XR generated $12.80 million in net product sales, exceeding the average estimate of $8.58 million, but representing a year-over-year decline of -20% [4] - Oxtellar XR reported $10.20 million in net product sales, below the average estimate of $12.29 million, with a significant year-over-year decrease of -62.1% [4] - Qelbree achieved $64.70 million in net product sales, slightly below the average estimate of $65.54 million, but showing a year-over-year increase of +43.5% [4] - Total net product sales amounted to $141.99 million, surpassing the average estimate of $140.61 million, reflecting a year-over-year growth of +2.6% [4] - Royalty revenues reached $7.84 million, exceeding the estimated $5.80 million, with a year-over-year increase of +51.2% [4] - GOCOVRI net product sales were $30.70 million, above the average estimate of $30.13 million, marking a year-over-year increase of +15.9% [4] - Other net product sales totaled $8.60 million, surpassing the average estimate of $7.38 million, with a year-over-year growth of +19.4% [4] - APOKYN reported $15 million in net product sales, below the average estimate of $16.70 million, reflecting a year-over-year decline of -10.2% [4] Stock Performance - Supernus shares returned +0.4% over the past month, while the Zacks S&P 500 composite increased by +11.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance against the broader market in the near term [3]

Supernus Pharmaceuticals (SUPN) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Supernus Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Vazzo of ICR Westwick, Investor Relation ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Exact name of registrant as specified in its charter) | Delaware | | | 20-2590184 | | --- | --- | --- | --- | | (State or other jurisdiction of | | | (I.R.S. Employer | | incorporation or organization) | | | Identification No.) | | 9715 Key West Avenue | Rockville | MD | 20850 | | (Address of principal executive offices) | | | (Zip Code) | (301) 838-2500 (Registrant's telephone number, including area code) (Ma ...

First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10 ...

Core Viewpoint - Supernus Pharmaceuticals (SUPN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook driven by an upward trend in earnings estimates [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which significantly influence stock price movements [4][6]. - Rising earnings estimates for Supernus suggest an improvement in the company's underlying business, likely leading to higher stock prices [5]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Supernus's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions for Supernus - For the fiscal year ending December 2025, Supernus is expected to earn $2.06 per share, reflecting a year-over-year decline of -34.4% [8]. - Over the past three months, the Zacks Consensus Estimate for Supernus has increased by 12.4%, indicating positive revisions from analysts [8].

ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to presen ...

A downtrend has been apparent in Supernus Pharmaceuticals (SUPN) lately with too much selling pressure. The stock has declined 20.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indic ...

Company Overview - Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [3][4] - The company's diverse neuroscience portfolio includes approved treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] Upcoming Events - Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the Barclays Global Healthcare Conference on March 11, 2025, with a fireside chat scheduled for 12:30 p.m. ET [1] - The company will also be present at the Jefferies Biotech on the Beach Summit on March 12, 2025 [1] Investor Relations - A live audio webcast of the fireside chat at the Barclays Global Healthcare Conference will be available on the company's website, with an archived replay accessible for 60 days post-conference [2]

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, Mass. Investors interested in arranging a meeting ...

Supernus Pharmaceuticals (SUPN) Q4 2024 Earnings Call February 26, 2025 02:53 AM ET Company Participants Peter Vozzo - Managing DirectorJack Khattar - CEO, President & DirectorTimothy Dec - Senior VP & CFOAndrew Tsai - SVPJack Padovano - Equity Research Associate - BioPharma Conference Call Participants Stacy Ku - AnalystDavid Amsellem - Sr. Research AnalystKristen Kluska - Managing Director, Biotechnology Equity Research Analyst Operator Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarte ...